Khavinson BioregulatorTarget: BladderUrinary

Vesilut

Vesilute · VESILUT · Bladder Cytogen · Glu-Asp bladder peptide · Везилут

Vesilut (Vesilute) is the bladder cytogen on the official NPCRIZ list - the SKU Western research-chem menus most often omit. Chitomur is the bladder Cytomax. Pielotax is kidney. Sequence listings in English are messy; treat HPLC as the identity check.

Not FDA-approved - research chemical

Quick answer

What it is: Vesilut (Vesilute) is the bladder cytogen on the official NPCRIZ list - the SKU Western research-chem menus most often omit.

Class and target: Cytogen (synthetic short peptide) · Urinary bladder · sequence ED

Typical research dose: 1–2 capsules/day (Cytomed) or 1–2 mg SC (research vial)

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team
Last updated: August 2026Evidence: Low3 peer-reviewed citations
Typical research dose
1–2 capsules/day (Cytomed) or 1–2 mg SC (research vial)
Frequency
1× daily for 10-30 day cycles
Half-life
Short (cytogen class)
Common vials
5 mg / 10 mg
CAS
N/A
Molecular weight
Dipeptide-class if ED; confirm COA

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

  • Longevity / aging3.5/10

    Khavinson-school tissue peptide. Single-lab concentration after haircut. Not a Western Phase 3 geroprotector.

  • Sexual / hormonal3/10

    Urinary/prostate aisle. Not a urology indication.

Compound card

Sequence
ED
Class
Khavinson cytogen (ED)
Formula
Short peptide (catalog often Glu-Asp; confirm COA)
Status
Not FDA-approved · research use
Dose it
5 mg + 2.5 mL BAC water → 2 mg/mL · 1000 mcg ≈ 50 units (U-100)
Open in calculator

How it works

Vesilut (Vesilute) is the synthetic bladder cytogen on the NPCRIZ/Cytomed poster - the SKU Western catalogs skip. It is not Chitomur (the bladder Cytomax complex), not Pielotax (kidney Cytomax), and not Vesugen (KED, vessels). English sequence tables often print Glu-Asp (ED); treat HPLC as identity.

The Khavinson organ map splits kidney from bladder on purpose. Stacking Vesilut with Chitomur is complex + cytogen of the same tissue. Stacking it with Pielotax is two organs in the urinary neighborhood.

Source: NPCRIZ cytogen list (VESILUT - bladder); class reviews PMID: 11713572

Khavinson map

Canonical 41
Class
Cytogen (synthetic short peptide)
Organ
Urinary bladder
Target
Bladder
System
Urinary
Sequence
ED · Glu-Asp (catalog; confirm COA - English sources disagree)
Pair
Chitomur (bladder Cytomax)
Везилут

Used in bioregulator stacks

Manufacturer-style organ combinations - not FDA protocols. Every name is a live leaf.

The Khavinson school

Vesilut is filed here as cytogen (synthetic short peptide), targeting the urinary bladder. Khavinson's St. Petersburg group moved from organ extracts (Cytamins) to capsule complexes (Cytomaxes) to synthetic short peptides (Cytogens); most of the evidence comes from that one group, with little independent Western replication.

Read the full background, the proposed epigenetic mechanism, the literature limits, and how we count the canonical 41 on the Khavinson bioregulators index.

History of this molecule

This leaf exists because the 41 is incomplete without it. e-peptide: “VESILUT - bladder peptide.” US catalogs skip it, then people invent a kidney cytogen that is not on the poster.

Glu-Asp (ED) shows up in some tables; other tables are silent. We list ED as catalog-common and flag the dispute. We do not invent a tetrapeptide to look complete.

Chitomur is the complex. Vesugen is vessels (KED) - another V-name trap.

Caveats

A defined sequence is not an FDA indication. Bladder cytogens sit in a Russian experimental-gerontology literature with limited Western replication. “Oral bioavailability because PEPT1” is real peptide-transport biology; it is not proof this SKU treats the organ disease. Gray-market identity is a live problem - HPLC is the only way to know the vial is the sequence on the label. Name collision with Vesugen (vessels) is how wrong vials get shipped.

Full 41-map: Khavinson bioregulators index · Bioregulator stacks

Research Use Cases

  • ✓Bladder tissue (research): Low

Dosing

PhaseDoseFrequencyNotes
Khavinson-style cytogen course1–2 capsules/day or 1–2 mg SCDaily for 10 days, 1-2x per yearManufacturer capsules vs research vials are different presentations. Not an OAB drug.

Administration

Route / form
Two real SKUs: Cytomed oral capsules (swallowed) or a lyophilized research vial reconstituted for subcutaneous injection. Nobody manufactures these as sublingual tablets.
Timing
Capsules: morning, about 30 minutes before meals. Research vial (SubQ): food does not change the injection.
Empty stomach?
Capsules: yes - Swallow on an empty stomach, about 30 minutes before meals. Reconstituted vial (SubQ): food does not change the injection. Cytomed boxes sometimes print “with food” because they are labeled as supplements; the manufacturer user-guide preference is before meals.

Vesilut: oral vs SubQ

Cytomed oral capsule
Bioavailability
No published human F% for this SKU. Di- and tripeptides can ride PEPT1/LAT; that is transporter biology, not proof the capsule treats the named organ. Cytomed cytogen capsules are swallowed.
Dose note
Vesilut Cytomed cytogen capsules: 1–2 capsules/day, typically 10–30 day courses. No reconstitution. Swallow; do not melt under the tongue. Swallowed with water. Morning, about 30 minutes before meals, is manufacturer user-guide folklore. Cytomed boxes sometimes print “with food” because they are labeled as supplements. That is not a published absorption RCT for this SKU. Pair: Chitomur is the bladder Cytomax. Pielotax is kidney. Vesugen is KED vessels. Three V-names, three organs.
Advantages
  • Official Cytomed cytogen SKU is a swallowed capsule. No BAC water, no syringe.
  • Matches how Cytomed ships the poster line.
  • Nobody manufactures this as a sublingual tablet.
  • If you can find the Cytomed capsule, it is the poster SKU. Swallow it. Do not invent a kidney cytogen that is not on the poster.
Considerations
  • Capsule milligrams are not 1–2 mg SC. Do not convert a research-vial protocol into capsule counts by arithmetic theater.
  • Empty-stomach timing is user-guide folklore plus PEPT1 logic, not a cited human PK study for this SKU.
  • Vesilut (id vesilute) is the bladder cytogen on the official NPCRIZ list, the SKU Western research-chem menus most often omit. It is not Vesugen and not Chitomur.
  • Not mirabegron. Overactive bladder belongs in urology.
Research vial SubQ
Bioavailability
No published human PK curve for this cytogen. Research-chem SubQ is the gray-market route. Class estimate is minutes-to-hours, not a depot ester.
Dose note
Research lyophilized vial: reconstitute with bacteriostatic water, sterile technique, SubQ. Class pattern is about 1–2 mg daily for on the order of 10 days, not a 12-week GLP-1 titration. Food does not change the injection. Do not convert Cytomed capsule counts into vial milligrams. Pair: Chitomur is the bladder Cytomax. Pielotax is kidney. Vesugen is KED vessels. Three V-names, three organs.
Advantages
  • Vial math is checkable if the COA matches the sequence on the label.
  • Food timing is irrelevant for SubQ.
  • Short pulsed courses match how the school used defined synthetics.
Considerations
  • Gray-market identity: HPLC is the only way to know the cake is ED (Glu-Asp, catalog; confirm COA).
  • Not a Western Phase 3. Russian experimental-gerontology literature is real and concentrated.
  • Not a sublingual tablet and not a Cytomax complex.
  • Vesilut (id vesilute) is the bladder cytogen on the official NPCRIZ list, the SKU Western research-chem menus most often omit. It is not Vesugen and not Chitomur.
  • English sequence listings disagree; Glu-Asp is catalog-common, not a tetrapeptide we invent to look complete. Demand HPLC.
  • Name collision with Vesugen is how wrong vials get shipped.
Recommendation: Two SKUs. Swallow Cytomed Vesilut capsules (no recon, not sublingual) or BAC-reconstitute a research vial for SubQ at the 1–2 mg / ~10-day class pattern. Food does not change the shot. Pair: Chitomur is the bladder Cytomax. Pielotax is kidney. Vesugen is KED vessels. Three V-names, three organs. Vesilut (id vesilute) is the bladder cytogen on the official NPCRIZ list, the SKU Western research-chem menus most often omit. It is not Vesugen and not Chitomur. Russian literature is real; Western Phase 3 is not. Western SEO lists that skip Vesilut are incomplete. NPCRIZ still sells it.

Timeline

Day 1-10 (course)
Tissue-identity signaling in the Khavinson bladder map - not a labeled antimuscarinic onset curve.

Who it is for

Bladder tissue (research)

Low

Cytogen pair to Chitomur. Not mirabegron. Not a kidney peptide.

Reconstitution

VialWaterConcentrationExample dose
Lyophilized cytogen (if the SKU is a vial)Follow the COA fillDo the mathCapsules skip this step. Cytomax complexes are not this molecule.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Research peptide / Cytomed cytogen. Not FDA-approved. Sequence identity on gray-market vials is unverified without HPLC. Do not confuse with Vesugen.

Regulatory & Legal Status

FDA Status (US)
Research Only

Bladder cytogen (Vesilut). Distinct from Chitomur (extract) and Vesugen (KED vessels). Not an OAB drug

WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

  • A defined sequence is not an FDA indication.
  • Gray-market identity is a live problem. HPLC beats a blog table.
  • Do not paste a sibling cytogen’s papers onto this SKU.
  • This site will not treat the named organ disease from a peptide page.

Verdict

Vesilut is the synthetic ED cytogen for Urinary bladder. Khavinson’s group published in this family. That is a concentrated literature, not a Western Phase 3. Capsules and vials are different SKUs.

Interactions & Contraindications

Research peptide / Cytomed cytogen. Not FDA-approved. Sequence identity on gray-market vials is unverified without HPLC. Do not confuse with Vesugen.

Frequently Asked Questions

Vesilut vs Vesugen vs Chitomur vs Pielotax?▼
Vesilut = bladder cytogen. Vesugen = KED vessel cytogen. Chitomur = bladder Cytomax. Pielotax = kidney Cytomax.
Why is this missing on other sites?▼
Western research-chem SEO copied each other’s 20-peptide lists. NPCRIZ still sells Vesilut.
Sequence?▼
Often listed as Glu-Asp. Confirm the COA. Do not assume KED (that is Vesugen).
OAB drug?▼
Not mirabegron. See urology for overactive bladder.
Oral capsule or injection?▼
Two SKUs. Cytomed Vesilut is a swallowed cytogen capsule (1–2/day, typical 10–30 day courses, morning empty-stomach folklore, no reconstitution, not a sublingual tablet). Research vials are BAC-reconstituted SubQ at about 1–2 mg for on the order of 10 days; food does not change the shot. Bladder cytogen, not Vesugen (vessels), not Chitomur (Cytomax), not Pielotax (kidney).

References

  1. Khavinson VKh et al. “Tissue-specific effects of peptides.” Bulletin of Experimental Biology and Medicine (2001). PMID: 11713572
  2. Khavinson VKh, Lin’kova NS, Tarnovskaya SI “Short peptides regulate gene expression.” Bulletin of Experimental Biology and Medicine (2016). PMID: 27909961
  3. Khavinson VKh, Morozov VG “Peptides of pineal gland and thymus prolong human life.” Neuroendocrinology Letters (2003). PMID: 14523363

📚 Related Articles

Khavinson Bioregulators: Vilon, Thymalin, Cortexin & the Russian Peptide Legacy
14 min read • Longevity

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →
← Back to Peptide Library·Bioregulator stacks